扬子江药业冲劲很足。去年11月,8亿元入股港股上市疫苗公司瑞科生物后,今年开年又有新动作。2月13日,业内多方消息报道称,荣昌生物前高管何如意或将加入扬子江药业,暂任首席医学官(CMO)一职。但截至目前,此消息尚未获得双方的正面回应。为什么何如意的新入职会引来业内热议?一方面是荣昌生物失去了一位猛将,另一方面是扬子江接下来是否会有大动作。资料显示,何如意博士在医药圈积累了30年的经验。他曾在美国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.